


# KalmCold

The Power of Andrographis for Strong Immune Health



#### The immune health market scenario



- Cold /Flu & Immunity is one of the fastest growing health categories
- Estimated to reach \$ 25 Billion by 2025\*\*
- Herbal extracts are the fastestgrowing ingredient, which is expected to grow at a CAGR of over 12% from 2020-2025.

#### Immunity and controlled inflammation



#### Andrographis paniculata



Unique botanical with immunostimulatory and healthy inflammatory response properties **Scientific name:** Andrographis paniculata

Family: Acanthaceae

Part used: Leaves, aerial parts

**English name:** King of Bitters, The Creat

Common Names: Kalmegh, Andrographis



Widely used in India, China and South East Asia as traditional medicine for managing common cold symptoms

#### Scientific evidence



3 Meta-analysis & 1 Systematic review of 45 clinical studies on *Andrographis paniculata* 



Reduced frequency & severity of cough symptoms<sup>1</sup>



Reduced cough & sore throat compared to placebo<sup>2</sup>



Shortened the duration of cough, sore throat & sick leave/time to resolution compared to usual care<sup>2</sup>



Improved overall symptoms compared to placebo & usual care<sup>2</sup>



Reduces the subjective symptoms of uncomplicated URTI<sup>3</sup>



Effective as an early support for acute URTI<sup>4</sup>


#### Reference

1. Wagner et al. Forsch Komplementmed. 2015;22(6):359-368 | 2. Hu et al. PLoS One. 2017 Aug 4;12(8):e0181780 | 3. Coon and Ernst E. Planta Medica 2004, 70(4): 293-298 | 4. Poolsup et al. Journal of Clinical Pharmacy and Therapeutics 2004, 29(1): 37-45.




KalmCold® is a fast-acting *Andrographis paniculata* with seven bioactives, clinically researched to work by healthy inflammatory response & immuno-stimulatory balance at a low dose

#### **Development of KalmCold®**



#### Unique phytochemical profile of AP-Bio®



## 7 Unique bioactive constituents of KalmCold®: Their actions on immunity and inflammation

Actives of KalmCold®	Mechanism	Effect
Andrographolide	Nitric oxide, iNOS, IL-1β, IL-6, TXB <sub>2</sub> , PGE <sub>2</sub> & IL-5	
Isoandrographolide	Nitric oxide, IL-1β, IL-6, TXB <sub>2</sub> & PGE <sub>2</sub>	
Neoandrographolide	Nitric oxide, PGE <sub>2</sub> , p38 mitogen activated protein kinase	Healthy
Andrograpanin	TNF-alpha, IL-6 and IL-12p70 and p38 mitogen activated protein kinase	inflammatory and Immuno- stimulation
Skullcapflavone-I	Nitric oxide, IL-6, TXB <sub>2</sub> , PGE <sub>2</sub> & LTB <sub>4</sub>	
7-O-methylwogonin	Nitric oxide, IL-1β, PGE <sub>2</sub> , LTB <sub>4</sub> & histamine	



## Healthy Inflammatory Clinical Study



## Research Findings of KalmCold®: Healthy-inflammatory response



Two randomized double-blind placebo-controlled study in subjects with symptoms of common cold<sup>1</sup>



References:


1. Saxena et al. Phytomedicine 2010, 17: 178-185. | 2. Chandrasekaran et al. Journal of Ethnopharmacology 2010, 129(2): 203-207. | 3. Chandrasekaran et al. International Immunopharmacology 2011, 11(1): 79-84. | 4. Chandrasekaran et al. Food and Chemical Toxicology 2009, 47: 1892-1902.

## Randomized placebo controlled clinical study of KalmCold® - Healthy-inflammatory response



Condition	Subjects with symptoms of upper respiratory tract infection	
Dose	200 mg and 400 mg	
Participants	200 adults (Age: 18-60 years)	
Duration	7 days	
Evaluation	Baseline, 6 hours, Day 2, Day 3, Day 5 and Day 7	
Outcome	KalmCold® 200mg and 400mg groups showed significantly better resolution of symptoms of uncomplicated upper respiratory tract infections when compared with placebo	


#### **Results – Subjective parameters**




- AP-Bio $^{\circ}$  showed prominent effects at day 3 and the efficacy is 1.6 times the placebo effects.
- Minimal clinical important difference was observed at day 3.

#### **Results-Objective parameters**

Effect of KalmCold® on Nasal mucosal weight



n=20 for each group; \* Baseline Vs Day 3 Effect of KalmCold® on Tissue counts




n=20 for each group; \* Baseline Vs Day 3

The objective parameters like nasal mucosal weight, number of tissue papers used showed a strong trend towards significant difference in both the KalmCold® groups when compared to the placebo group.

#### Results- Objective parameters: IL-8 and cold symptoms

Effect of KalmCold® on IL-8



n=20 for each group;


- IL-8 is a major cytokine of human nasal epithelium, readily produced upon virus infection including influenza virus A.
- IL-8 concentrations are high in individuals with acute respiratory infection.
- IL-8 concentration correlates with symptom severity/Global severity.
- IL-8 has a strong correlation with the nasal domain of acute respiratory infection illness and in fact most strongly with three specific symptoms: runny nose, plugged nose, and sneezing

## Randomized double-blind placebo controlled clinical study of KalmCold® - Healthy-inflammatory response


Condition	Subjects with symptoms of common cold
Dose	200 mg per day
Participants	223 adults (Age: 18-60 years)
Duration	5 days
Evaluation	Day 1, Day 3, and Day 5 (using Visual Analogue Scale)
Outcome	KalmCold® showed 2 times efficacy as compared to placebo and was well tolerated

#### **Results**

#### Reduction in common cold symptoms



#### Overall symptoms score



KalmCold® showed 2 times efficacy as compared to placebo and was well tolerated


**Preclinical Study** 


#### Role of inflammatory mediators in common cold



Reference: Roxas and Jurenka. Alternative Medicine Review 2007, 12(1): 25-48.

#### KalmCold® reduces inflammatory mediators








#### Immuno-stimulatory Clinical Study

## Research Findings of KalmCold®: Immuno-stimulatory activity



A prospective open label, single centre, single-arm study of KalmCold® on immuno-stimulatory activity




## A prospective open label, single centre, single-arm study of KalmCold® - Immuno-stimulatory activity




Condition	Healthy volunteers
Dose	100 mg twice a day
Participants	30 adults
Duration	30 days
Evaluation	Screening day, day 3, day 7, day 30
Outcome	KalmCold® supports immunity by increasing INF gamma, IL-4 coupled by increased CD4+ and absolute lymphocytes count and decreasing IL-2

#### **Results- Effect on immune cells**












KalmCold® increased CD3+ cells

#### Results- Effect on immune cell mediators







KalmCold® increased INF gamma


KalmCold® increased IL 4

KalmCold® decreased IL 2

#### Clinical Outcomes-Immuno-stimulatory activity

#### AP-Bio® improves immunity evident from:

Increased INF gamma | Increased IL-4 | Increased CD4+ and CD3+ | Increased absolute lymphocytes count | Decreased IL-2






**Preclinical Study** 


## KalmCold® increases the activity of phagocytes and NK cells



#### **Phagocytes**




**Natural Killer Cells** 






#### **Phagocytosis**

Increases the activity of phagocytes



#### **Natural Killer Cells**

Increases the activity of NK cells



Destroys tumour cells

#### Safety of KalmCold®



#### **Safety study**

Non-mutagenic (battery of in vitro tests) 4 Non-toxic (up to 5000 mg/kg, p.o. in rats) 4



## KalmCold® supports immune health by immunostimulatory and healthy- inflammatory balance



Possible health claims and Dose of KalmCold®:

- Supports immunity\*
- Positively modulates immune response\*
- Helps to reduce symptoms of common cold and upper respiratory tract infections, such as sore throat, cough, runny nose, fatigue and fever\*
- Support immune function and to relieve
   symptoms of mild fever, common cold and sore
   throat\*
- Maintains healthy inflammatory response & immuno-stimulatory balance\*

Dosage 200 - 400 mg per day

#### Making a difference at every step through sustainability



Andrographis for KalmCold® is cultivated using Good Agricultural Practices. . We procure our seeds from a government-approved agency, which assures their authenticity. Plants are not harvested until they are fully grown and flowering, ensuring their optimal phytochemical composition.



We minimize our carbon footprint by cultivating mostly with non-fossil fuels and without machinery that uses the fossil fuels. We reuse the water used for growing the botanical crop.



During manufacturing/ processing, most of the power utilized is from hydro and solar energy sources.



We are an ISO14001-certified (environmental management) organization, and our manufacturing facility is surrounded by trees to provide a green belt.

#### Top brands containing KalmCold®/ AP-Bio®






























#### Top brands containing KalmCold®/ AP-Bio®

















#### Cost per Dose and Million doses sold of KalmCold®

#### Cost per dose:

>800 Million doses sold till date

#### Scientific publications on KalmCold®

O1 Saxena et al. Phytomedicine 2010, 17(3-4): 178-85.	Chandrasekaran et al. Journal of Ethnopharmacology 2010, 129 (2): 203-207.
Chandrasekaran et al. International Immunopharmacology 2011, 11(1): 79-84.	Chandrasekaran et al. Food and Chemical Toxicology 2009, 47(8): 1892-02.

## Accreditations, certifications, and registration for KalmCold®













USFDA inspected site









Non Irradiated

Pesticide residue complies to USP

Heavy metal complies to USP



TGA






Certificate No.: TC-5527

GLP certified testing facility

#### Why choose KalmCold®?



#### Watch this video to learn more



hiips://www.youtube.com/watch?v=oxbtuTAbwTc&t=2s



# KalmCold Thank you

This is a business to business communication material and the statements used here have not been evaluated by any regulatory authorities. The ingredients mentioned here are not intended to diagnose, treat, cure or prevent any disease.